Pharmaceutical & Biotech
News and Insights
Outcomes-based pricing is on the rise
Outcomes-based pricing is on the rise in the US. Currently about 14% of US payers have at least on pay-for-performance pricing arrangement, this is up from 10% in 2014. The pluses are that discounts and rebates will rise if a drug is performing well. If a drug not performing well, rebates will decrease. A couple of glitches with the outcomes-based pricing are patients adhering to their prescription plan for usage and the need for expansion of the current electronic data collection system. Click here to view the entire article. ...
Boehringer Ingelheim starting a rewards program for COPD patients
In an effort to help patients adhere to their treatment plan, Boehringer Ingleheim is beginning a new rewards program for those using Spriva Respimat for the treatment of COPD. Patients will earn points for prescription refills, daily medication check-ins and taking quizzes and surveys. These points can then be used to purchase gift cards a companies such as Starbucks and Amazon. If all goes well, Boehringer plans to extend the rewards program to include its 5 other drugs for asthma and COPD. Click here to read the entire article. ...
2016 ASCO Conference
The American Society of Clinical Oncology's (ASCO) annual meeting brings together 30,000 oncology professionals from around the world. This year's meeting is being held in Chicago, IL. The conference begain on June 3rd and ends on June 7th. It is a chance to attend educational sessions, discover new therapies and learn about trends in the industry. To learn a little about what happened at the 2016 conference please click here. ...
Big Pharma Executives are Moving to Small Biotech Start-ups
Here is an interesting article on the reasoning behind why more and more executives from Big Pharma to are moving on to lead small start-up Biotechs. The small companies offer the classic high-risk, high-reward contrast and the freedom from bureaucracy or politics. Additionally, in recent years more drugs that received approval were created at these small start-ups. Click here to view the entire article. ...
How to look good for your Skype interview
Please take a minute to view this 4 minute video with tips and guidance on how to look your best for an upcoming Skype interview. The four basic steps include: sound, location, good lighting and dressing appropriately. ...
Amgen – ‘Breakaway from Cancer’ Campaign
Patrick Dempsey, who played a doctor on "Grey's Anatomy" is starring in a new campaign for Amgen to help fight cancer. The campaign supports efforts for the prevention of cancer, support for those battling the disease, provides financial assistance and aids survivors. Dempsey's mother died from ovarian cancer in 2014. He founded the Patrick Dempsey Center for Cancer Hope & Healing in 2008. Click here to view the entire article ...
Changes coming to Novartis
In an effort to show the importance of oncology to Novartis, it will be splitting the company into two business units. One will be focused on cancer and the second on other drugs. Additionally, David Epstein, who has been with Novartis since 1989, will be departing the company later this year to pursue new opportunities in the US. He will be replaced by two people. Paul Hudson is coming over from AstraZeneca to lead the pharmaceutical business unit and Bruno Strigini, who currently head of Novartis Oncology, will take over as lead the newly created oncology business. Click here to view the entire article. ...
Express Scripts to implement a new program
In an effort to deter companies from increasing prices on older drugs, Express Scripts is starting a "market events" program that allow them to act quickly when a company unexplainably raises prices for older drugs. This is in response to Turing and Valeant 's increasing pricing for certain therapies this past year. The program will be optional to both employers and health insured clients. Customers that sign up will allow Express Scripts to move patients to lower-priced alternatives when an old drug's price increases. Click here to view the entire article. ...
Teva - Allergan deal scheduled to close in June
Teva is on track to finish its $40.5 billion dollar buy of Allergan's generics unit. The deal has been in the works since last summer and with recent ending of the Pfizer/Allergan buyout shareholders have been nervous. Click here to view the entire article. ...
Shire to build a biologics plant in Ireland
Shire is expected to begin construction on a $400 million biologics plant in Peircetown, Ireland this summer. The plant will employ 400 individuals and is expected to be completed in 2019. Currently, Shire only has manufacturing plants in the US. Shire CEO Flemming Ornskov said, "Increasing our biologics manufacturing capability is fundamental to achieving our ambition of becoming the world's leading Biotechnology Company focused on rare diseases and other specialty conditions." Click here to view the entire article. ...
1 of 3